It was reported that ACLY was acetylated at K540, K546, and K554 by p300/CBP-associated factor (PCAF), which blocked poly-ubiquitination at these sites and stabilized ACLY under high-glucose conditions, lipid synthesis, and tumor growth [51]. The gene discussed is KAT2B; the disease is neoplasm.